SEC Comment Letter 0000000000-23-013986 to TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc.
Date: Dec. 21, 2023 · CIK: 0001826667 · Accession: 0000000000-23-013986
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276070
Letter
United States securities and exchange commission logo December 21, 2023 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 Re:TriSalus Life Sciences, Inc. Registration Statement on Form S-1 Filed December 15, 2023 File No. 333-276070 Dear Mary Szela: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Juan Grana at 202-551-6034 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Matt Browne, Esq.
Show Raw Text
United States securities and exchange commission logo
December 21, 2023
Mary Szela
Chief Executive Officer
TriSalus Life Sciences, Inc.
6272 W. 91st Ave.
Westminster, Colorado 80031
Re:TriSalus Life Sciences, Inc.
Registration Statement on Form S-1
Filed December 15, 2023
File No. 333-276070
Dear Mary Szela:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Juan Grana at 202-551-6034 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Matt Browne, Esq.